Human ITGAL/CD11A/LFA-1 ORF/cDNA clone-Lentivirus plasmid (NM_001114380)

Cat. No.: pGMLP000685
Size: 10 µg
Concentration: generally 0.5ug/ul, usually not less than 0.3ug/ul
Leading Time: 3-7 working days

Pre-made Human ITGAL/CD11A/LFA-1 Lentiviral expression plasmid for ITGAL lentivirus packaging, ITGAL lentivirus production, overexpression stable cell line development, cell transient transfection and gene delivery targeting T/B/NK cells, macrophages, cardiomyocytes, hepatocytes, and neurons.

Our GM-Lentiviral vector is seamlessly integrated with the GM lentivirus packaging system. Discover more about the GM lentivirus packaging system.

pdf Datasheet
pdf MSDS
pdf Terms of Use
Target products collection

Go to CD11a/Integrin Alpha L/ITGAL/ITGAL/CD11A products collection>>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

Purchase
Total Price: $1604.4
Shipping fee: Limited-time free
For payment issues, contact us.


Product Description

Catalog ID pGMLP000685
Gene Name ITGAL
Accession Number NM_001114380
Gene ID 3683
Species Human
Product Type Lentivirus plasmid (overexpression)
Insert Length 3261 bp
Gene Alias CD11A,LFA-1,LFA1A
Fluorescent Reporter ZsGreen
Mammalian Cell Selection Puromyocin
Fusion Tag 3xflag (C-Terminal)
Promoter CMV
Resistance Amplicin
ORF Nucleotide Sequence ATGAAGGATTCCTGCATCACTGTGATGGCCATGGCGCTGCTGTCTGGGTTCTTTTTCTTCGCGCCGGCCTCGAGCTACAACCTGGACGTGCGGGGCGCGCGGAGCTTCTCCCCACCGCGCGCCGGGAGGCACTTTGGATACCGCGTCCTGCAGGTCGGAAACGGGGTCATCGTGGGAGCTCCAGGGGAGGGGAACAGCACAGGAAGCCTCTATCAGTGCCAGTCGGGCACAGGACACTGCCTGCCAGTCACCCTGAGAGGTTCCAACTATACCTCCAAGTACTTGGGAATGACCTTGGCAACAGACCCCACAGATGGAAGCATTTTGTTTGCTGCTGTTCAGTTTTCCACAAGCTACAAAACAGAATTTGATTTCTCAGATTATGTTAAACGGAAGGACCCTGATGCTCTGCTGAAGCATGTAAAGCACATGTTGCTGTTGACCAATACCTTTGGTGCCATCAATTATGTCGCGACAGAGGTGTTCCGGGAGGAGCTGGGGGCCCGGCCAGATGCCACCAAAGTGCTTATCATCATCACGGATGGGGAGGCCACTGACAGTGGCAACATCGATGCGGCCAAAGACATCATCCGCTACATCATCGGGATTGGAAAGCATTTTCAGACCAAGGAGAGTCAGGAGACCCTCCACAAATTTGCATCAAAACCCGCGAGCGAGTTTGTGAAAATTCTGGACACATTTGAGAAGCTGAAAGATCTATTCACTGAGCTGCAGAAGAAGATCTATGTCATTGAGGGCACAAGCAAACAGGACCTGACTTCCTTCAACATGGAGCTGTCCTCCAGCGGCATCAGTGCTGACCTCAGCAGGGGCCATGCAGTCGTGGGGGCAGTAGGAGCCAAGGACTGGGCTGGGGGCTTTCTTGACCTGAAGGCAGACCTGCAGGATGACACATTTATTGGGAATGAACCATTGACACCAGAAGTGAGAGCAGGCTATTTGGGTTACACCGTGACCTGGCTGCCCTCCCGGCAAAAGACTTCGTTGCTGGCCTCGGGAGCCCCTCGATACCAGCACATGGGCCGAGTGCTGCTGTTCCAAGAGCCACAGGGCGGAGGACACTGGAGCCAGGTCCAGACAATCCATGGGACCCAGATTGGCTCTTATTTCGGTGGGGAGCTGTGTGGCGTCGACGTGGACCAAGATGGGGAGACAGAGCTGCTGCTGATTGGTGCCCCACTGTTCTATGGGGAGCAGAGAGGAGGCCGGGTGTTTATCTACCAGAGAAGACAGTTGGGGTTTGAAGAAGTCTCAGAGCTGCAGGGGGACCCCGGCTACCCACTCGGGCGGTTTGGAGAAGCCATCACTGCTCTGACAGACATCAACGGCGATGGGCTGGTAGACGTGGCTGTGGGGGCCCCTCTGGAGGAGCAGGGGGCTGTGTACATCTTCAATGGGAGGCACGGGGGGCTTAGTCCCCAGCCAAGTCAGCGGATAGAAGGGACCCAAGTGCTCTCAGGAATTCAGTGGTTTGGACGCTCCATCCATGGGGTGAAGGACCTTGAAGGGGATGGCTTGGCAGATGTGGCTGTGGGGGCTGAGAGCCAGATGATCGTGCTGAGCTCCCGGCCCGTGGTGGATATGGTCACCCTGATGTCCTTCTCTCCAGCTGAGATCCCAGTGCATGAAGTGGAGTGCTCCTATTCAACCAGTAACAAGATGAAAGAAGGAGTTAATATCACAATCTGTTTCCAGATCAAGTCTCTCATCCCCCAGTTCCAAGGCCGCCTGGTTGCCAATCTCACTTACACTCTGCAGCTGGATGGCCACCGGACCAGAAGACGGGGGTTGTTCCCAGGAGGGAGACATGAACTCAGAAGGAATATAGCTGTCACCACCAGCATGTCATGCACTGACTTCTCATTTCATTTCCCGGTATGTGTTCAAGACCTCATCTCCCCCATCAATGTTTCCCTGAATTTCTCTCTTTGGGAGGAGGAAGGGACACCGAGGGACCAAAGGGCGGGCAAGGACATACCGCCCATCCTGAGACCCTCCCTGCACTCGGAAACCTGGGAGATCCCTTTTGAGAAGAACTGTGGGGAGGACAAGAAGTGTGAGGCAAACTTGAGAGTGTCCTTCTCTCCTGCAAGATCCAGAGCCCTGCGTCTAACTGCTTTTGCCAGCCTCTCTGTGGAGCTGAGCCTGAGTAACTTGGAAGAAGATGCTTACTGGGTCCAGCTGGACCTGCACTTCCCCCCGGGACTCTCCTTCCGCAAGGTGGAGATGCTGAAGCCCCATAGCCAGATACCTGTGAGCTGCGAGGAGCTTCCTGAAGAGTCCAGGCTTCTGTCCAGGGCATTATCTTGCAATGTGAGCTCTCCCATCTTCAAAGCAGGCCACTCGGTTGCTCTGCAGATGATGTTTAATACACTGGTAAACAGCTCCTGGGGGGACTCGGTTGAATTGCACGCCAATGTGACCTGTAACAATGAGGACTCAGACCTCCTGGAGGACAACTCAGCCACTACCATCATCCCCATCCTGTACCCCATCAACATCCTCATCCAGGACCAAGAAGACTCCACACTCTATGTCAGTTTCACCCCCAAAGGCCCCAAGATCCACCAAGTCAAGCACATGTACCAGGTGAGGATCCAGCCTTCCATCCACGACCACAACATACCCACCCTGGAGGCTGTGGTTGGGGTGCCACAGCCTCCCAGCGAGGGGCCCATCACACACCAGTGGAGCGTGCAGATGGAGCCTCCCGTGCCCTGCCACTATGAGGATCTGGAGAGGCTCCCGGATGCAGCTGAGCCTTGTCTCCCCGGAGCCCTGTTCCGCTGCCCTGTTGTCTTCAGGCAGGAGATCCTCGTCCAAGTGATCGGGACTCTGGAGCTGGTGGGAGAGATCGAGGCCTCTTCCATGTTCAGCCTCTGCAGCTCCCTCTCCATCTCCTTCAACAGCAGCAAGCATTTCCACCTCTATGGCAGCAACGCCTCCCTGGCCCAGGTTGTCATGAAGGTTGACGTGGTGTATGAGAAGCAGATGCTCTACCTCTACGTGCTGAGCGGCATCGGGGGGCTGCTGCTGCTGCTGCTCATTTTCATAGTGCTGTACAAGGTTGGTTTCTTCAAACGGAACCTGAAGGAGAAGATGGAGGCTGGCAGAGGTGTCCCGAATGGAATCCCTGCAGAAGACTCTGAGCAGCTGGCATCTGGGCAAGAGGCTGGGGATCCCGGCTGCCTGAAGCCCCTCCATGAGAAGGACTCTGAGAGTGGTGGTGGCAAGGACTGA
ORF Protein Sequence MKDSCITVMAMALLSGFFFFAPASSYNLDVRGARSFSPPRAGRHFGYRVLQVGNGVIVGAPGEGNSTGSLYQCQSGTGHCLPVTLRGSNYTSKYLGMTLATDPTDGSILFAAVQFSTSYKTEFDFSDYVKRKDPDALLKHVKHMLLLTNTFGAINYVATEVFREELGARPDATKVLIIITDGEATDSGNIDAAKDIIRYIIGIGKHFQTKESQETLHKFASKPASEFVKILDTFEKLKDLFTELQKKIYVIEGTSKQDLTSFNMELSSSGISADLSRGHAVVGAVGAKDWAGGFLDLKADLQDDTFIGNEPLTPEVRAGYLGYTVTWLPSRQKTSLLASGAPRYQHMGRVLLFQEPQGGGHWSQVQTIHGTQIGSYFGGELCGVDVDQDGETELLLIGAPLFYGEQRGGRVFIYQRRQLGFEEVSELQGDPGYPLGRFGEAITALTDINGDGLVDVAVGAPLEEQGAVYIFNGRHGGLSPQPSQRIEGTQVLSGIQWFGRSIHGVKDLEGDGLADVAVGAESQMIVLSSRPVVDMVTLMSFSPAEIPVHEVECSYSTSNKMKEGVNITICFQIKSLIPQFQGRLVANLTYTLQLDGHRTRRRGLFPGGRHELRRNIAVTTSMSCTDFSFHFPVCVQDLISPINVSLNFSLWEEEGTPRDQRAGKDIPPILRPSLHSETWEIPFEKNCGEDKKCEANLRVSFSPARSRALRLTAFASLSVELSLSNLEEDAYWVQLDLHFPPGLSFRKVEMLKPHSQIPVSCEELPEESRLLSRALSCNVSSPIFKAGHSVALQMMFNTLVNSSWGDSVELHANVTCNNEDSDLLEDNSATTIIPILYPINILIQDQEDSTLYVSFTPKGPKIHQVKHMYQVRIQPSIHDHNIPTLEAVVGVPQPPSEGPITHQWSVQMEPPVPCHYEDLERLPDAAEPCLPGALFRCPVVFRQEILVQVIGTLELVGEIEASSMFSLCSSLSISFNSSKHFHLYGSNASLAQVVMKVDVVYEKQMLYLYVLSGIGGLLLLLLIFIVLYKVGFFKRNLKEKMEAGRGVPNGIPAEDSEQLASGQEAGDPGCLKPLHEKDSESGGGKD

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    Category Cat No. Products Name
    Biosimilar GMP-Bios-INN-931 Pre-Made Odulimomab Biosimilar, Fab Fusion, Anti-Itgal Antibody: Anti-CD11A/LFA-1/LFA1A therapeutic antibody
    Biosimilar GMP-Bios-INN-981 Pre-Made Rovelizumab Biosimilar, Bispecific, Anti-Itgal;Itgb2 Antibody: Anti-CD11A/LFA-1/LFA1A;CD18/LAD/LCAMB/LFA-1/MAC-1/MF17/MFI7 therapeutic antibody
    Biosimilar GMP-Bios-ab-166 Pre-Made Efalizumab biosimilar, Whole mAb, Anti-ITGAL Antibody: Anti-CD11A/LFA-1/LFA1A therapeutic antibody
    Target Antibody GM-Tg-g-T35640-Ab Anti-ITAL/ ITGAL/ CD11A monoclonal antibody
    Target Antigen GM-Tg-g-T35640-Ag ITGAL VLP (virus-like particle)
    ORF Viral Vector pGMLP000685 Human ITGAL Lentivirus plasmid
    ORF Viral Vector vGMLP000685 Human ITGAL Lentivirus particle


    Target information

    Target ID GM-T35640
    Target Name CD11a/Integrin Alpha L/ITGAL
    Gene Group Identifier
    （Target Gene ID in Homo species)         		3683
    Gene ID 100065508 (Equus caballus), 101085940 (Felis catus), 16408 (Mus musculus), 281874 (Bos taurus)
    308995 (Rattus norvegicus), 3683 (Homo sapiens), 489905 (Canis lupus familiaris), 711945 (Macaca mulatta)
    Gene Symbols & Synonyms ITGAL,Itgal,Cd11a,LFA-1,Ly-15,Ly-21,(p180),LFA-1A,CD11A,LFA1A
    Target Alternative Names (p180),CD11 antigen-like family member A,CD11A,CD11a,Cd11a,ITGAL,Integrin Alpha L,Integrin alpha-L,Itgal,LFA-1,LFA-1A,LFA1A,Leukocyte adhesion glycoprotein LFA-1 alpha chain (LFA-1A),Leukocyte function-associated molecule 1 alpha chain,Ly-15,Ly-21
    Uniprot Accession P20701,P24063,P61625
    Additional SwissProt Accessions: P24063,P61625,P20701
    Uniprot Entry Name
    Protein Sub-location Transmembrane Protein
    Category Therapeutics Target, INN Index
    Disease cancer
    Disease from KEGG Rap1 signaling pathway, Cell adhesion molecules, Natural killer cell mediated cytotoxicity, Leukocyte transendothelial migration, Regulation of actin cytoskeleton, Malaria, Staphylococcus aureus infection, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Rheumatoid arthritis, Viral myocarditis
    Gene Ensembl ENSECAG00000008485, ENSMUSG00000030830, ENSBTAG00000007103, ENSG00000005844, ENSCAFG00845013917, ENSMMUG00000016876
    Target Classification Tumor-associated antigen (TAA)


    About GMVC

    GDU

    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.